Skip to main content
Erschienen in: BMC Infectious Diseases 1/2020

Open Access 01.12.2020 | Case report

Continuous ambulatory peritoneal dialysis-associated Histoplasma capsulatum peritonitis: a case report and literature review

verfasst von: Thanat Ounsinman, Piriyaporn Chongtrakool, Nasikarn Angkasekwinai

Erschienen in: BMC Infectious Diseases | Ausgabe 1/2020

Abstract

Background

Fungal peritonitis (FP) is a rare complication of peritoneal dialysis. We herein describe the second case in Asia of Histoplasma capsulatum peritonitis associated with continuous ambulatory peritoneal dialysis (CAPD).

Case presentation

An 85-year-old woman with end-stage renal disease (ESRD) who had been on CAPD for 3 years and who had a history of 3 prior episodes of peritonitis presented with intermittent abdominal pain for 2 weeks and high-grade fever for 3 days. Elevated white blood cell (WBC) count and rare small oval budding yeasts were found in her peritoneal dialysis (PD) fluid. From this fluid, a white mold colony was observed macroscopically after 7 days of incubation, and numerous large, round with rough-walled tuberculate macroconidia along with small smooth-walled microconidia were observed microscopically upon tease slide preparation, which is consistent with H. capsulatum. The peritoneal dialysis (PD) catheter was then removed, and it also grew H. capsulatum after 20 days of incubation. The patient was switched from CAPD to hemodialysis. The patient was successfully treated with intravenous amphotericin B deoxycholate (AmBD) for 2 weeks, followed by oral itraconazole for 6 months with satisfactory result. The patient remains on hemodialysis and continues to be clinically stable.

Conclusion

H. capsulatum peritonitis is an extremely rare condition that is associated with high morbidity and mortality. Demonstration of small yeasts upon staining of PD fluid, and isolation of slow growing mold in the culture of clinical specimen should provide important clues for diagnosis of H. capsulatum peritonitis. Prompt removal of the PD catheter and empirical treatment with amphotericin B or itraconazole is recommended until the culture results are known.
Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
AmBD
Amphotericin B deoxycholate
CAPD
Continuous ambulatory peritoneal dialysis
CBC
Complete blood count
CT
Computed tomography
ESRD
End-stage renal disease
FP
Fungal peritonitis
HR
Heart rate
HU
Hounsfield unit
PD
Peritoneal dialysis
RBC
Red blood cell
WBC
White blood cell

Background

Fungal peritonitis (FP) is a rare and serious complication of chronic peritoneal dialysis (PD), and it is associated with a high rate of hospitalization, catheter removal, permanent transfer to hemodialysis, and death [1]. Although FP is primarily suspected in patients with prior antibiotic use within 3 months [2, 3], early diagnosis of FP still remains challenging since it is difficult to distinguish from bacterial peritonitis. Candida spp. was the predominant pathogen causing FP in many previous studies [4]. FP caused by fungi other than Candida spp. is only rarely reported. Herein, we report a case and literature review of fungal peritonitis caused by Histoplasma capsulatum that presented with fever and subacute-onset of abdominal pain.

Case presentation

An 85-year-old woman with end-stage renal disease (ESRD) presented with abdominal discomfort and high-grade fever for 2 days. She was diagnosed ESRD in 2017, and has been treated with peritoneal dialysis (PD) since then. Two weeks after catheter insertion, she had difficulty draining infused dialysate fluid due to catheter malposition, which required repositioning of Tenckhoff catheter owing to partial catheter obstruction from a fibrin clot. Since that revision, she has been on continuous ambulatory peritoneal dialysis (CAPD) without further mechanical complication. However, there were 3 episodes of CAPD-related infection that occurred within 6 months of her most recent admission.
The first episode started in August 2019 when she had cloudy PD fluid effluent without fever or abdominal complaint. Peritoneal fluid analysis showed white blood cell count (WBC) of 268 cells/mm3, with 55% neutrophils, 37% lymphocytes, and 8% eosinophils. Culture-negative PD-associated peritonitis was diagnosed since blood and PD fluid cultures for aerobic bacteria reported no growth. She was successfully treated with intraperitoneal cefazolin and ceftazidime for 14 days. The second episode occurred in September 2019. Due to recurrent catheter malposition from omental wrapping, she underwent a second revision of her PD catheter. After the operation, she had a high-grade fever with non-specific organ symptoms. PD fluid analysis showed a WBC count of 103 cells/mm3, with 65% neutrophils, 21% lymphocytes, and 10% eosinophils. Blood and PD fluid culture for aerobic bacteria were no growth. Computed tomography (CT) of the whole abdomen revealed no intra-abdominal collection, and that the tip of the PD catheter was in the proper position. She then gradually improved with a reduction of WBC in PD fluid to 7 cells/mm3 after treatment with intraperitoneal cefazolin and ceftazidime for 14 days. The third episode occurred near the end of December 2019 when she presented with a high-grade fever, nausea, and vomiting, but without any remarkable physical findings. Two sets of blood culture revealed alpha-hemolytic streptococci. PD fluid analysis revealed a WBC count of 14 cells/mm3 without differential count due to a low cell count, and culture revealed a rare colony of alpha-hemolytic streptococci. Streptococcal PD-associated peritonitis and septicemia were diagnosed, and she was successfully treated with intravenous ceftriaxone for 14 days. Fungal culture of PD fluid was not sent during any of the first three episodes of culture negative peritonitis.
In January 2020 or 2 weeks prior to her most recent admission, she was complaining of intermittent abdominal pain during drainage of dialysate fluid from her abdomen and a low-grade fever for 3 days. Her PD fluid effluent had also become cloudy. She was febrile with a temperature of 38.2 ͦ C, but reported no abdominal tenderness on physical examination. PD fluid analysis revealed a WBC count of 380 cells/mm3, with 86% neutrophils, 11% lymphocytes, and 1% eosinophils. She was then empirically treated with intraperitoneal vancomycin and ceftazidime. Gram stain of PD fluid revealed few polymorphonuclear cells with no observed bacteria; however, small oval budding yeasts were demonstrated. PD fluid culture for bacteria was sent. The culture for fungus was first sent after recurrent peritonitis that occurred within the past 5 months. Therefore, oral fluconazole 100 mg/day was given concurrently with intraperitoneal antibiotic administration. After intraperitoneal antibiotic and fluconazole treatment for one week, her fever and abdominal pain were gradually improved. Peritoneal fluid analysis showed a marked decrease in white cell count (1 cell/mm3), culture of dialysis fluid showed no evidence of bacterial growth, and fungal culture was still pending.
Despite treatment with intraperitoneal antibiotic and oral fluconazole 100 mg daily for 2 weeks, she developed recurrent abdominal discomfort, loss of appetite, cloudy PD effluent for 3 days, and high-grade fever for 1 day prior to admission. She was then admitted on 24 January 2020. On examination, her body temperature was 38.4 °C, and generalized abdominal tenderness was found. All other examination findings, including investigation for PD catheter exit site infection, were unremarkable.
Initial laboratory investigations of complete blood count (CBC) revealed a WBC count of 11,340/μL, with 83.5% neutrophils, 9.5% lymphocytes, and 0.2% eosinophils; a hemoglobin level of 9.9 g/dL; and, a platelet count of 295,000 /μL. Blood chemistry showed a high level of creatinine, which was consistent with her renal disease. Analysis of her PD fluid effluent showed an elevated WBC count of 278 cells/mm3, with 92% neutrophils, 8% lymphocytes, and rare red blood cells (RBC). Gram stain of the dialysate effluent still demonstrated rare small oval budding yeasts (Fig. 1). A CT scan of her abdomen revealed diffuse smooth thickened enhancing peritoneum with a moderate amount of turbid ascites (18–21 HU) along the mesentery and in the pelvic cavity. Localized fixation of small bowel loops within the thickened peritoneum was also found, which is suggestive of early sclerosing encapsulating peritonitis (Fig. 2).
She was empirically treated with intravenous meropenem 500 mg/day, vancomycin 500 mg every 72 h, and amphotericin B deoxycholate (AmBD) 0.7 mg/kg/day. The Tenckhoff catheter was removed on the day after admission due to suspected fungal peritonitis. Intraoperative finding revealed turbid dialysate fluid and fibrotic scar at the exit site of the peritoneal dialysis catheter. Renal replacement therapy was switched to intermittent hemodialysis via a newly inserted temporary double-lumen catheter at the right internal jugular vein. Bacterial culture reported no growth thereafter. After two weeks of hemodialysis, a white colony of mold was observed macroscopically from a fungal culture taken two weeks prior to admission (Fig. 3). Microscopic morphology from PD fluid culture demonstrated numerous large, rounded with rough-walled tuberculate macroconidia along with small smooth-walled microconidia, which is consistent with H. capsulatum (Fig. 4). Another specimen of PD fluid also demonstrated the same pathogen.
The final diagnosis was CAPD-associated H. capsulatum peritonitis. Intravenous AmBD at a dose of 0.7 mg/kg/day was continued for a total of 2 weeks, followed by oral itraconazole capsule 600 mg daily for 3 days, and 200 mg twice daily thereafter. Our patient’s abdominal pain and fever were gradually improved. She was discharged and subsequently given a course of oral itraconazole 200 mg twice daily for a total duration of 6 months. The patient was continued on hemodialysis and is currently stable. No adverse event of itraconazole was observed during follow-up.

Discussion

CAPD-associated H. capsulatum peritonitis is an extremely rare infectious complication in chronic PD patients. Approximately 3–6% of all peritonitis episodes in patients undergoing PD were caused by fungus, and Candida spp. is the most often reported group of fungal pathogens [3]. Similarly, nationwide surveillance in Thailand during 2009 to 2010 found FP in approximately 6% of culture-positive peritonitis in CAPD patients [5]. Reported complications of FP in CAPD included inability to continue CAPD, longer length of hospitalization, and high mortality [6].
Due to the rarity of this case, we performed systematic literature searches of the Medline databases for articles published from 1985 to 2020. No language restriction was applied and reference lists of all included studies were manually searched for other potentially eligible studies. Our search results revealed that no cohort or case control studies of CAPD-associated H. capsulatum peritonitis have been published. We identified only 7 case reports of H. capsulatum peritonitis in CAPD patients published over the past three decades (Table 1). Most cases were reported from endemic region of Histoplasma spp. or areas where there had been an outbreak of histoplasmosis, as follows: 4 cases from the United States [710], and 2 cases from Brazil [11, 12]. The one case reported from Asia was reported from Hong Kong [13]. However, sporadic cases of histoplasmosis have been reported throughout the world, especially in AIDS patients [14]. We herein report the second case in Asia of isolated H. capsulatum peritonitis in a CAPD patient.
Table 1
Literature review for previously reported cases of CAPD-associated Histoplasma capsulatum peritonitis
No.
Reported year, country
Age/ gender
Duration of CAPD
Previous BP (No.)
Clinical presentation
PD fluid analysis
Catheter removal
Treatment
Reference
1
2018, USA
63/F
4 years
Yes (2)
Abdominal pain, fever
WBC 2173 cells/mm3, 96% Ne
No
NA
[7]
2
2012, USA
75/M
> 2 years
Yes (2)
Abdominal pain, fever
WBC 562 cells/mm3
Yes
ITZ for 1 year
[8]
3
2010, USA
62/M
4 years
No
Abdominal pain, no fever
WBC 180 cells/mm3, 41% Ne
Yes
ITZ for 6 months
[9]
4
2006, USA
27/F
NA
NA
Cloudy PD
WBC 377 cells/mm3, 88% Ne
Yes
AmBD for 2 weeks and ITZ for 2 months
[10]
5
1994, Brazil
64/F
4 months
No (1)
Abdominal pain, cloudy PD
WBC 2133 cells/mm3, 95% Ne
Yes
AmBD, unknown duration
[11]
6
1993, Brazil
50/F
2 years
NA
Abdominal pain, fever
NA
Yes
AmBD, unknown duration
[12]
7
1991, Hong Kong
46/M
2 years
Yes (1)
Abdominal pain, fever
WBC 370 cells/mm3
No
FCZ, 5-FC, AmBD, unknown duration
[13]
Abbreviations: AmBD amphotericin B, BP bacterial peritonitis, CAPD continuous ambulatory peritoneal dialysis, F female, FCZ fluconazole, ITZ itraconazole, M male, Ne neutrophil, No. number, PD peritoneal dialysis, WBC white blood cell, 5-FC flucytosine, USA United States of America, NA not available
Diagnosis of H. capsulatum peritonitis requires a high degree of suspicion. In addition to it being a rare disease, a lack of specific symptoms and signs make it’s difficult to differentiate from bacterial peritonitis. Previous episode of bacterial peritonitis and failure to respond to initial empirical antibiotic treatment for common bacteria should prompt the attending physician to consider a diagnosis of infection with unusual organisms [3]. Microbiological laboratory testing can also help to facilitate an early diagnosis of histoplasmosis. H. capsulatum stains poorly with Gram stain, so it is rarely detected by this method. Calcofluor white, which is a fluorescent stain that binds chitin in the cell wall of all fungi, is useful for identifying H. capsulatum in clinical specimens. Careful examination of special staining of PD fluid may, thus, help in making a provisional diagnosis of H. capsulatum peritonitis. Among the 7 cases shown in Table 1, the WBC count in PD fluid varied from 180 to 2173 cells/mm3. Isolation of H. capsulatum remains the gold standard for diagnosis of histoplasmosis. When incubated on appropriate medium at 25 to 30 °C, growth of the mycelial phase occurs most commonly within 2 to 3 weeks, but may take up to 8 weeks [15]. If positive, characteristic large with rough-walled tuberculate macroconidia (7 to 15 μm in size) and small smooth-walled microconidia (2 to 6 μm in size) will be demonstrated.
According to guidelines issued by the International Society for Peritoneal Dialysis (ISPD) in 2016, the administration of antifungal agents and immediate catheter removal are recommended when fungi are identified in PD effluent [16]. Both interventions lower the risk of recurrent fungal peritonitis and death [6]. The PD catheter was removed in 5 of the 7 cases in previous reports. Intravenous AmBD has poor peritoneal bioavailability and flucytosine is not widely available, so other agents, including azole drugs and echinocandin, have been frequently used to treat Candida spp. and filamentous fungi [16]. However, intravenous AmBD and itraconazole are listed as recommended drugs for treatment of histoplasmosis. No specific recommendation was provided for the duration of treatment of H. capsulatum peritonitis [17]. Most previous reports described 6–12 months of oral itraconazole with or without initial intravenous AmBD or flucytosine [710]. Our patient received 2 weeks of AmBD followed by 6 months of oral itraconazole, and she had a good response to treatment.
In conclusion, H. capsulatum peritonitis is an extremely rare condition that is associated with high morbidity and mortality. Demonstration of small yeasts upon staining of PD fluid, and isolation of slow growing mold in the culture of clinical specimen should provide important clues for diagnosis of H. capsulatum peritonitis. Prompt removal of the PD catheter and empirical treatment with amphotericin B or itraconazole is recommended until the culture results are known.

Acknowledgements

The authors gratefully acknowledge the patient profiled in this report for formally permitting us to report details relating to her case.
All clinical and demographic data were collected in accordance with the local ethics committee from Siriraj Institutional Review Board of the Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, and the patient profiles in this report gave written informed consent to be studied, reported on in this study.
The patient gave written informed consent for publication of clinical details and images in this study.

Competing interests

The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Nadeau-Fredette A-C, Bargman JM. Characteristics and outcomes of fungal peritonitis in a modern north American cohort. Perit Dial Int. 2015;35(1):78–84.CrossRef Nadeau-Fredette A-C, Bargman JM. Characteristics and outcomes of fungal peritonitis in a modern north American cohort. Perit Dial Int. 2015;35(1):78–84.CrossRef
2.
Zurück zum Zitat Levallois J, Nadeau-Fredette A-C, Labbé A-C, Laverdière M, Ouimet D, Vallée M. Ten-year experience with fungal peritonitis in peritoneal dialysis patients: antifungal susceptibility patterns in a north-American center. Int J Infect Dis. 2012;16(1):e41–3.CrossRef Levallois J, Nadeau-Fredette A-C, Labbé A-C, Laverdière M, Ouimet D, Vallée M. Ten-year experience with fungal peritonitis in peritoneal dialysis patients: antifungal susceptibility patterns in a north-American center. Int J Infect Dis. 2012;16(1):e41–3.CrossRef
3.
Zurück zum Zitat Matuszkiewicz-Rowinska J. Update on fungal peritonitis and its treatment. Perit Dial Int. 2009;29(Suppl 2):S161–5.CrossRef Matuszkiewicz-Rowinska J. Update on fungal peritonitis and its treatment. Perit Dial Int. 2009;29(Suppl 2):S161–5.CrossRef
4.
Zurück zum Zitat García Agudo R, García-Martos P. Clinical and microbiological aspects of fungal peritonitis in peritoneal dialysis. Nefrol Engl Ed. 2009;29(6):506–17. García Agudo R, García-Martos P. Clinical and microbiological aspects of fungal peritonitis in peritoneal dialysis. Nefrol Engl Ed. 2009;29(6):506–17.
5.
Zurück zum Zitat Kanjanabuch T, Chancharoenthana W, Katavetin P, Sritippayawan S, Praditpornsilpa K, Ariyapitipan S, et al. The incidence of peritoneal dialysis-related infection in Thailand: a nationwide survey. J Med Assoc Thail. 2011;94(Suppl 4):S7–12. Kanjanabuch T, Chancharoenthana W, Katavetin P, Sritippayawan S, Praditpornsilpa K, Ariyapitipan S, et al. The incidence of peritoneal dialysis-related infection in Thailand: a nationwide survey. J Med Assoc Thail. 2011;94(Suppl 4):S7–12.
6.
Zurück zum Zitat Miles R, Hawley CM, McDonald SP, Brown FG, Rosman JB, Wiggins KJ, et al. Predictors and outcomes of fungal peritonitis in peritoneal dialysis patients. Kidney Int. 2009;76(6):622–8.CrossRef Miles R, Hawley CM, McDonald SP, Brown FG, Rosman JB, Wiggins KJ, et al. Predictors and outcomes of fungal peritonitis in peritoneal dialysis patients. Kidney Int. 2009;76(6):622–8.CrossRef
7.
Zurück zum Zitat Ijaz A, Choudhury D. A case of rare, fungal peritonitis caused by Histoplasma capsulatum in a patient on CAPD. Nat Rev Nephrol. 2010;6(7):435–9.CrossRef Ijaz A, Choudhury D. A case of rare, fungal peritonitis caused by Histoplasma capsulatum in a patient on CAPD. Nat Rev Nephrol. 2010;6(7):435–9.CrossRef
8.
Zurück zum Zitat Jain M, Revankar SG. A case of peritoneal histoplasmosis in a patient receiving chronic ambulatory peritoneal dialysis. Mycoses. 2012;55(1):99–100.CrossRef Jain M, Revankar SG. A case of peritoneal histoplasmosis in a patient receiving chronic ambulatory peritoneal dialysis. Mycoses. 2012;55(1):99–100.CrossRef
9.
Zurück zum Zitat Marcic SM, Kammeyer PL, Aneziokoro C, Bartnicki L, Yong S, Leehey DJ. ‘Culture-negative’ peritonitis due to Histoplasma capsulatum. Nephrol Dial Transplant. 2006;21(10):3002.CrossRef Marcic SM, Kammeyer PL, Aneziokoro C, Bartnicki L, Yong S, Leehey DJ. ‘Culture-negative’ peritonitis due to Histoplasma capsulatum. Nephrol Dial Transplant. 2006;21(10):3002.CrossRef
10.
Zurück zum Zitat Sardar A, Thajudeen B, Kadambi PV. Histoplasma Peritonitis: An Extremely Rare Complication of Peritoneal Dialysis. Case Rep Nephrol. 2018;2018:8015230.PubMedPubMedCentral Sardar A, Thajudeen B, Kadambi PV. Histoplasma Peritonitis: An Extremely Rare Complication of Peritoneal Dialysis. Case Rep Nephrol. 2018;2018:8015230.PubMedPubMedCentral
11.
Zurück zum Zitat Lopes JO, Alves SH, Benevenga JP, Rosa AC. The second case of peritonitis due to Histoplasma capsulatum during continuous ambulatory peritoneal dialysis in Brazil. Mycoses. 1994;37(5–6):161–3.CrossRef Lopes JO, Alves SH, Benevenga JP, Rosa AC. The second case of peritonitis due to Histoplasma capsulatum during continuous ambulatory peritoneal dialysis in Brazil. Mycoses. 1994;37(5–6):161–3.CrossRef
12.
Zurück zum Zitat Lopes JO, Alves SH, Benevenga JP, Regio OR, Calil A. Histoplasma capsulatum peritonitis associated with continuous ambulatory peritoneal dialysis. Mycopathologia. 1993;122(2):101–2.CrossRef Lopes JO, Alves SH, Benevenga JP, Regio OR, Calil A. Histoplasma capsulatum peritonitis associated with continuous ambulatory peritoneal dialysis. Mycopathologia. 1993;122(2):101–2.CrossRef
13.
Zurück zum Zitat Lim W, Chau SP, Chan PCK, Cheng IKP. Histoplasma capsulatum infection associated with continuous ambulatory peritoneal dialysis. J Inf Secur. 1991;22(2):179–82. Lim W, Chau SP, Chan PCK, Cheng IKP. Histoplasma capsulatum infection associated with continuous ambulatory peritoneal dialysis. J Inf Secur. 1991;22(2):179–82.
14.
Zurück zum Zitat Bahr NC, Antinori S, Wheat LJ, Sarosi GA. Histoplasmosis infections worldwide: thinking outside of the Ohio River valley. Curr Trop Med Rep. 2015;2(2):70–80.CrossRef Bahr NC, Antinori S, Wheat LJ, Sarosi GA. Histoplasmosis infections worldwide: thinking outside of the Ohio River valley. Curr Trop Med Rep. 2015;2(2):70–80.CrossRef
15.
Zurück zum Zitat Azar MM, Hage CA. Laboratory diagnostics for Histoplasmosis. J Clin Microbiol. 2017;55(6):1612–20.CrossRef Azar MM, Hage CA. Laboratory diagnostics for Histoplasmosis. J Clin Microbiol. 2017;55(6):1612–20.CrossRef
16.
Zurück zum Zitat Li PK-T, Szeto CC, Piraino B, de Arteaga J, Fan S, Figueiredo AE, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment. Perit Dial Int. 2016;36(5):481–508.CrossRef Li PK-T, Szeto CC, Piraino B, de Arteaga J, Fan S, Figueiredo AE, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment. Perit Dial Int. 2016;36(5):481–508.CrossRef
17.
Zurück zum Zitat Wheat J, Sarosi G, McKinsey D, Hamill R, Bradsher R, Johnson P, et al. Practice guidelines for the Management of Patients with Histoplasmosis. Clin Infect Dis. 2000;30(4):688–95.CrossRef Wheat J, Sarosi G, McKinsey D, Hamill R, Bradsher R, Johnson P, et al. Practice guidelines for the Management of Patients with Histoplasmosis. Clin Infect Dis. 2000;30(4):688–95.CrossRef
Metadaten
Titel
Continuous ambulatory peritoneal dialysis-associated Histoplasma capsulatum peritonitis: a case report and literature review
verfasst von
Thanat Ounsinman
Piriyaporn Chongtrakool
Nasikarn Angkasekwinai
Publikationsdatum
01.12.2020
Verlag
BioMed Central
Erschienen in
BMC Infectious Diseases / Ausgabe 1/2020
Elektronische ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-020-05441-5

Weitere Artikel der Ausgabe 1/2020

BMC Infectious Diseases 1/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.